Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.

Published Date: 19 Apr 2023

Pediatric patients with solid tumors exhibiting DNA replication stress and/or DNA repair responded favorably to a combination of the investigational ATR inhibitor ceralasertib and the PARP inhibitor olaparib (Lynparza).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Five-year survival in patients with unresectable hepatocellular carcinoma sets milestone

2.

Survey: Record Numbers of US Adults Report Depression.

3.

Increased Exercise May Lower the Risk of Prostate Cancer.

4.

Integrating MRD in Myeloma: Guidance for Therapy Escalation and De-escalation

5.

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot